Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity

Lancet

Volumn 356, Issue 9228, 2000, Pages 461-465

  Cobelens, Frank G J ^a   Van Deutekom, Henk ^b   Draayer Jansen, Inez W E ^c   Schepp Beelen, Ank C H M ^d   Van Gerven, Paul J H J ^e   Van Kessel, Rob P M ^c   Mensen, Marlies E A ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c Municipal Health Service   (Netherlands)

^d Municipal Medical and Health Service of The Hague   (Netherlands)

^e Public Health Service of the Rotterdam Region   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; ENDEMIC DISEASE; FEMALE; FOLLOW UP; HUMAN; INFECTION RISK; MALE; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR; TRAVEL; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0034609280     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02554-X     Document Type: Article

References (29)

1. Morger H., Steffen R., Schar M. Epidemiology of cholera in travellers, and conclusions for vaccination recommendations. BMJ. 286:1983;184-186.
2. Shope R.E., Evans A.S. Assessing geographic and transport factors, and recognition of new viruses. Morse S.S. Emerging viruses. 1993;Oxford University Press, New York.
3. Raviglione M.C., Snider D.E., Kochi A. Global epidemiology of tuberculosis. morbidity and mortality of a worldwide epidemic JAMA. 273:1995;220-226.
4. Pablos-Mendez A., Raviglione M.C., Laszlo A.et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med. 338:1998;1641-1649.
5. Anon. The risk and prevention of tuberculosis in travellers. Can Comm Dis Rep 1997; 23: 1-8.
6. Houston S. Tuberculosis risk and prevention in travelers - what about BCG? J Travel Med. 4:1997;76-82.
7. Comstock G.W., Livesay V.T., Woolpert S.F. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 99:1974;131-138.
8. Menzies R., Vissandjee B. Effect of bacille Calmette-Guérin vaccination in tuberculin reactivity. Am Rev Respir Dis. 145:1992;621-625.
9. Richards N.M., Nelson K.E., Batt M.D., Hackbarth D., Heidenreich J.G. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis. 120:1979;59-65.
10. Snider D.E. The tuberculin skin test. Am Rev Respir Dis. 125:1982;108-118.
11. Murray C.J.L., Styblo K., Rouillon A. Tuberculosis in developing countries. burden, intervention and cost Bull Int Union Tuber Lung Dis. 65:1990;6-24.
12. van Embden J.D., Cave M.D., Crawford J.T.et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting. recommendations for a standardized methodology J Clin Microbiol. 31:1993;406-409.
13. Bleiker M.A., Sutherland I., Styblo K., ten Dam H.G., Misljenovic O. Guidelines for estimating the risks of tuberculous infection from tuberculin test results in a representative sample of children. Bull Int Union Tuber Lung Dis. 64:1989;7-12.
14. Steffen R., Kane M.A., Shapiro C.N., Billo N., Schoellhorn K.J., van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA. 272:1994;885-889.
15. Lobel H.O., Phillips-Howard P.A., Brandling-Bennett A.D.et al. Malaria incidence and prevention among European and north American travellers to Kenya. Bull World Health Organ. 68:1990;209-215.
16. Behrens R.H., Roberts J.A. Is travel prophylaxis worthwhile? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers. BMJ. 309:1994;918-922.
17. Koch S., Steffen R. Meningococcal disease in travelers. vaccination recommendations J Travel Med. 1:1994;4-7.
18. Broekmans J.F. Evaluation of applied strategies in low-prevalence countries. Reichman L.B., Hershfeld E.S. Tuberculosis: a comprehensive international approach. 1993;Marcel Dekker, New York.
19. Styblo K. Recent advances in epidemiological research in tuberculosis. Adv Tuber Res. 20:1980;1-63.
20. Thompson N.J., Glassroth J.L., Snider D.E., Farer L.S. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis. 119:1979;587-597.
21. Bruins J. Mantoux skin testing and isoniazid prophylaxis in The Netherlands Army: improving on existing tools [PhD thesis]. Rotterdam: Erasmus University, 1998.
22. Palmer C.E., Edwards L.B. Identifying the tuberculous infected. the dual-test technique JAMA. 205:1968;167-169.
23. Edwards L.B., Acquaviva F.A., Livesay V.T. Identification of tuberculous infected. dual tests and density of reaction Am Rev Respir Dis. 108:1973;1334-1339.
24. Bleiker MA. Onderzoek naar de prevalentie van specifieke en niet-specifieke tuberculine gevoeligheid bij schoolkinderen in Delft in de periode 1966-1991. Report TNO-Gezondheidsonderzoek, Rijswijk: 1992.
25. von Reyn C.F., Green P.A., McCormick D.et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative. an open study of patients with M avium complex infection or tuberculosis Clin Infect Dis. 19:1994;15-20.
26. Rieder H.L. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuber Lung Dis. 76:1995;114-121.
27. Borgdorff M.W., Verhage C., Kalisvaart N.A., Veen J. Mantoux test. quality of reading and change of tuberculin Ned Tijdschr Geneeskd. 143:1999;1398-1400.
28. Cobelens F.G.J., de Boer H.E.L. Specificity of the mantoux test with the new tuberculin RT23 compared with the formerly used PPD-RIVM; a comparative study in hospital personnel. Ned Tijdschr Geneeskd. 143:1999;885-888.
29. Colditz G.A., Brewer T.F., Berkey C.S.et al. Efficacy of BCG vaccine in the prevention of tuberculosis. meta-analysis of the published literature JAMA. 271:1994;698-702.